Shares of Allogene Therapeutics (ALLO) have lost nearly 23% year to date, underperforming the industry’s 7.0% decline. The stock has also underperformed the sector and the S&P 500 during the same period, as shown in the chart below. ALLO’s shares are trading below the 50 and 200-day moving averages.ALLO Stock Underperforms Industry, Sector & S&P 500 Image Source: Zacks Investment ResearchThe decline in stock price can be attributed to the strategic changes in Allogene’s pipeline, announced at the start of t ...

Allogene Therapeutics (ALLO) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Since a changing ea ...

Company Overview - Allogene Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune diseases [3] - The company aims to provide "off-the-shelf" CAR T cell product candidates that are readily available on-demand, more reliably, and at greater scale to a larger patient population [3] Upcoming Events - Allogene will participate in two investor conferences in December 2024, including the Citizens JMP Hematology and Oncology Summit on December 2 and the 36th Annual Piper Sandler Healthcare Conference on December 3 [2] - The presentation time for the Jefferies London Healthcare Conference on November 20, 2024, has been updated to 11:30 AM GMT / 6:30 AM ET [2] Communication and Accessibility - Webcasts of the presentations will be available on the company's website under the Investors tab in the News and Events section, with replays accessible for approximately 30 days [2]

Allogene Therapeutics (ALLO) incurred an adjusted loss (excluding impairment of long-lived asset) of 27 cents per share in third-quarter 2024, narrower than the Zacks Consensus Estimate of a loss of 34 cents.Inclusive of impairment charges, the company posted a loss of 32 cents per share in the quarter. In the year-ago period, the company reported a loss of 37 cents. There was no impairment charge in the year-ago period.Allogene did not generate revenues during the reported quarter. The Zacks Consensus Esti ...

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q3 2024 Results Conference Call November 7, 2024 5:00 PM ET Company Participants Christine Cassiano - Chief Corporate Affair and Brand Strategy Officer David Chang - President and Chief Executive Officer Zachary Roberts - EVP of Research and Development and Chief Medical Officer Geoff Parker - Chief Financial Officer Conference Call Participants Michael Yee - Jefferies Jack Allen - Baird Biren Amin - Piper Sandler John Newman - Canaccord Genuity Luca Issi - RBC Capi ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ________________________________________________________ FORM 10-Q ________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe ...

Exhibit 99.1 Allogene Therapeutics Reports Third Quarter 2024 Financial Results and Business Update • Cemacabtagene Ansegedleucel (Cema-Cel): 1L Consolidation Large B-Cell Lymphoma (LBCL) ◦ Pivotal Phase 2 ALPHA3 Trial Continuing with Site Activation and Patient Screening/Enrollment ◦ Lymphodepletion Selection Planned for Mid-2025 ◦ Enrollment Completion Expected in 1H 2026 with Primary EFS Data by YE 2026 ◦ Potential BLA Submission in 2027 • ALLO-329 in Autoimmune Disease (AID) ◦ Pre-Clinical Data Highligh ...

Phase 1 TRAVERSE Trial Demonstrated a Single Infusion of ALLO-316 Can Yield an Overall Response Rate of 50% and Confirmed Response Rate of 33% in Patients with CD70 Tumor Proportion Score (TPS) of Greater than 50%TRAVERSE Trial Highlights the Ability of CD70 Dagger® Technology to Promote Robust Expansion and Persistence of ALLO-316 with Standard Lymphodepletion, Validating its Potential as the Next Generation Allogeneic Platform ALLO-316 Demonstrated a Manageable Safety Profile; Newly Implemented Diagnostic ...

Conference Call and Webcast Scheduled for November 7, 2024 at 2:00 p.m. PT/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will report third quarter 2024 financial results and provide a business update on November 7, 2024, after the close of the market. The announcement wi ...

Allogene Therapeutics, Inc. (ALLO, Financial) saw a significant drop in its stock price, falling 5.06% to $2.54 per share. The trading volume reached 1.41 million shares, with a turnover rate of 0.67% and a volatility of 4.49%.Recent financial reports show that the company recorded no revenue, a net loss of $66.36 million, an earnings per share (EPS) of -$0.35, and a gross loss of $3.64 million, resulting in a price-to-earnings (P/E) ratio of -1.60. Among the 18 institutions covering the stock, 72% recommen ...